AmerisourceBergen Named Top Pharmaceutical Distributor in National Survey of Hospital Executives
Goldman, Sachs Investment Research's Third National Survey of Hospital
Executives Rated AmerisourceBergen The Overall
Best Pharmaceutical Distributor
VALLEY FORGE, Pa., Sep 19, 2002 (BUSINESS WIRE) -- In a recently published national survey of hospital executives conducted by Goldman, Sachs & Co. Investment Research, AmerisourceBergen Corporation (NYSE:ABC) was rated the number one national pharmaceutical distributor.
A statistically reliable sampling of hospital executives was asked to rate each of the national pharmaceutical distributors on service reputation, price competitiveness, and order/pricing accuracy. AmerisourceBergen was number one overall, and rated highest in service reputation and order/pricing accuracy.
AmeriSource Health Corporation, which merged with Bergen Brunswig Corporation last year to create AmerisourceBergen, was the top rated company in the two prior years of the survey.
"We are extremely pleased that we again have been selected the top pharmaceutical distributor by hospital executives, especially with all the merger activities of the past year," said R. David Yost, AmerisourceBergen's President and Chief Executive Officer. "Customer service continues to be the focus of AmerisourceBergen, and we know we must earn this rating each year."
AmerisourceBergen (NYSE:ABC) is the largest pharmaceutical services company in the United States dedicated solely to the pharmaceutical supply chain. It is the leading distributor of pharmaceutical products and services to the hospital systems and acute care market, alternate care facilities, independent community pharmacies, and regional chain pharmacies.
The Company is also a leader in the institutional pharmacy marketplace. With more than $40 billion in annualized operating revenue, AmerisourceBergen is headquartered in Valley Forge, PA, and employs more than 13,000 people serving over 25,000 customers.
This press release may contain certain "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These statements are based on management's current expectations and are subject to uncertainty and changes in circumstances.
Actual results may vary materially from the expectations contained in the forward-looking statements. The forward-looking statements herein include statements addressing future financial and operating results of AmerisourceBergen and the benefits and other aspects of the merger between Amerisource Health Corporation and Bergen Brunswig Corporation.
The following factors, among others, could cause actual results to differ materially from those described in the forward-looking statements: the risk that the businesses of AmeriSource and Bergen Brunswig will not be integrated successfully; failure to obtain and retain expected synergies; and other economic, business, competitive and/or regulatory factors affecting the business of AmerisourceBergen generally.
More detailed information about these factors is set forth in AmerisourceBergen's filings with the Securities and Exchange Commission, including its Annual Report on Form 10-K for fiscal 2001, its Quarterly Reports on Form 10-Q for the first and second quarters of fiscal 2002, and the joint proxy statement-prospectus for the merger as filed on August 1, 2001.
AmerisourceBergen is under no obligation to (and expressly disclaims any such obligation to) update or alter any forward-looking statements whether as a result of new information, future events or otherwise.
CONTACT: AmerisourceBergen Michael N. Kilpatric, 610/727-7118 email@example.com